On January 13, 2025, Roivant Science Ltd made two major purchases, $336.9 million for each. The first purchase was the shares of Immunovant Inc. (NASDAQ:IMVT) and the companys own stock ROIV.
In the first transaction, Sciences Roivant served both as a director and 10% owner of Immunovant Inc., it acquired 16,845,010 shares of IMVT for $20 per share. Roivant now holds 96,650,341 shares of Immunovant after the insider purchase of $336.9 million.
Immunovant is a clinical-stage biopharmaceutical company focused on the development of treatments for autoimmune diseases through monoclonal antibodies targeting the neonatal Fc receptor FcRn.
With $635 million of cash and cash equivalent in the end of 2024, the financial position of Immunovant gives a decent signal that the company can pay its $250 million annual business expenses when it had zero sales revenue for years since inception in 2018.
Sciences Roivant on the latter purchase executed a $336.9 million stock buyback under a $1.5 billion repurchase program that was authorized. Shares repurchase returns value to shareholder and improving the investor confidence.
Industry analysts are waiting and watching to see how these investments will position both companies to become more profitable.
You can make more informed investment decisions by visiting GuruFocus now and deep dive into Immunovant and Roivant Sciences' performance with charts, breakdowns, insiders, screeners and more!
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。